Floatz Rating
B57/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02420912CT.gov Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chromosome 17p Deletion
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | M.D. Anderson Cancer Center | P2 | B · 57 |
| Dexasone | Fondazione EMN Italy Onlus | P2 | BB |
| Fludarabine | Institute of Hematology & Blood Diseases Hospital, China | P2 | BB |
| Melphalan | Institute of Hematology & Blood Diseases Hospital, China | P2 | B |
| Cyclophosphamide | City of Hope Medical Center | P2 | B |
| Tacrolimus | City of Hope Medical Center | P2 | B |
| Cytarabine | Fred Hutchinson Cancer Center | P2 | B |
| Camustine | Fred Hutchinson Cancer Center | P2 | B |
| Atorvastatin | Fred Hutchinson Cancer Center | P2 | B |
+10 more in the Chromosome 17p Deletion cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nivolumab in Chromosome 17p Deletion. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-chromosome-17p-deletion
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →